Derek Archila, an analyst from Wells Fargo, maintained the Hold rating on Sutro Biopharma (STRO – Research Report). The associated price target is $8.00.
Derek Archila has given his Hold rating due to a combination of factors including Sutro Biopharma’s consistent pipeline execution and the anticipation of few significant data releases in the near term. While management is effectively advancing their research, particularly with Luvelta’s ongoing REFRaME-01 study and potential expansion opportunities, there is uncertainty about the availability of data from the initial patient groups. This creates a level of unpredictability regarding the company’s immediate growth catalysts.
Additionally, Derek Archila’s analysis suggests that while Sutro Biopharma ended the fourth quarter with a robust cash position, providing a cash runway into the second half of 2025, the stock performance is expected to be constrained within a certain range due to the lack of major stock-moving events this year. Despite the stock being down compared to the broader market, the company’s year is centered around execution which may not translate into significant stock price movements in the short term, leading to the Hold rating.
According to TipRanks, Archila is a 4-star analyst with an average return of 8.4% and a 43.96% success rate. Archila covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Exelixis, and Argenx Se.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Sutro Biopharma (STRO) Company Description:
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
